Compare Abbott Laboratories (ABT) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Banco Santander SA — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Banco Santander SA trades at $13.55 (market cap $203.67B). The key difference: Banco Santander SA is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SAN | |
|---|---|---|
Market Cap | $166.94B | $203.67B |
Sector | Health | Financials |
52-Week High | $136.62 | $14.37 |
52-Week Low | $82.57 | $8.31 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Banco Santander (SAN) trades at $14.19, up 1.72% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.72% net income margin and 16.18% ROE, though recent quarters saw EPS misses. Recent developments include the completion of the TSB acquisition and AI-driven efficiency initiatives, positioning the company for growth amid positive analyst sentiment.
The outlook for SAN is cautiously optimistic, with upside driven by cost-saving measures and strategic acquisitions. Risks include regulatory scrutiny in Spain and volatile cash flows. Analysts maintain a 64% buy rating, highlighting value potential, but investors should monitor execution on profitability targets and macroeconomic impacts on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
